Join Dr. Greenblatt to examine the links between the MTHFR gene and folate – and the impact a deficiency in folate (B9) has on mental illness. You’ll learn evidence-based testing strategies to inform folate augmentation and/or repletion, and how to incorporate precision medicine genetic tools into your practice from Dr. Daniel Dowd of Genomind.



Overview

Deficiency of the essential nutrient folate (Vitamin B9) is well-established as a risk factor for a range of neuropsychiatric conditions and low folate levels are consistently correlated with psychiatric symptom severity. In addition to diet, folate status is powerfully moderated by the MTHFR enzyme, as well as the gene that codes for it. MTHFR mutations can substantially impair folate metabolism and influence individual requirements for folate repletion and maintenance.

In this webinar, Dr. Greenblatt will present evidence-based strategies for MTHFR gene testing and blood folate testing to inform targeted protocols for folate augmentation and/or repletion.

Dr. Daniel Dowd, Genomind’s Senior Vice President of Medical Affairs, will also join us for this webinar, to talk about how you can incorporate their precision medicine tools into your practice.

This webinar is sponsored by Genomind, whose mission is to optimize the treatment experience for individuals and healthcare providers by unlocking the value of precision medicine through actionable genetic insights and innovative health technology. Learn more about Genomind below!


Enroll & Watch Now

Instructors

James Greenblatt, MD

Founder, Chief Medical Officer

Dr. James M. Greenblatt is a pioneer in functional and integrative psychiatry and a board-certified child and adult psychiatrist who has been treating patients since 1988. He serves as an Assistant Clinical Professor of Psychiatry at Tufts University School of Medicine and Dartmouth’s Geisel School of Medicine. An internationally recognized speaker on  nutritional interventions in mental health and prolific author, Dr. Greenblatt has written nine books, including his newest book, Finally Hopeful; the bestsellers Finally Focused: The Breakthrough Natural Treatment Plan for ADHD, Answers to Anorexia (updated edition, 2021), Functional & Integrative Medicine for Antidepressant Withdrawal, and Nutritional Lithium: The Untold Tale of a Mineral That Transforms Lives and Heals the Brain—the definitive guide to lithium’s role in psychiatry. He is also the founder of Psychiatry Redefined, an educational platform dedicated to transforming psychiatric care through integrative and evidence-based approaches.

Daniel Dowd, PharmD

Dr. Daniel Dowd is Genomind’s Chief Clinical Officer. His responsibilities at Genomind include building and managing a mental health medical affairs team of PharmDs and PhDs. Dr. Dowd is also intimately involved with product development, genetic research, medical education programs and pharmacy integrations. He is a PharmD licensed in New York and New Jersey and has over 15 years of unique experience across community pharmacy management, medical affairs and healthcare education. Prior to joining Genomind, Dr. Dowd held positions as district and regional director of community pharmacy training and operations for several pharmacies including Rite Aid and A&P. For 13 years, he also developed and taught advanced pharmacology courses at the City University of New York (CUNY). Dr. Dowd has published on the implementation of pharmacogenetics in psychiatry and has been interviewed by national media outlets, including Drug Topics, JAMA Medical News and Perspectives and the Dr. Oz show. He is a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the American Society of Pharmacovigilance STRIPE Collaborative Community.


Our mission is to optimize the treatment experience for individuals and healthcare providers by unlocking the value of precision medicine through actionable genetic insights and innovative health technology.

 

Every year millions of people struggle through trial-and-error treatment or encounter preventable health complications due to adverse drug events. Annually, the societal costs to the healthcare industry are over $358 billion. Until recently, the information to help reduce guesswork, identify adverse drug events, and make personalized treatment decisions was lacking.

There is no one-size-fits all treatment, and Genomind’s platform was developed to unlock the potential of truly personalized medicine. With our comprehensive precision health platform, healthcare providers can quickly assess drug-drug, gene-drug, and drug-drug-gene interactions to deliver safer and more targeted approaches to treatment.

While our heritage is rooted in mental health PGx testing, we have grown to include a broader scope of conditions. Keeping a keen focus on the customer experience and maintaining a deep understanding of challenges faced in our health system, we create innovative solutions that make a meaningful difference in the lives of millions. Together, we can reduce costs, improve quality of care and increase patient and healthcare provider satisfaction.

That’s the science behind better.